189 related articles for article (PubMed ID: 23357766)
1. A physiologically based pharmacokinetic model of rifampin in mice.
Lyons MA; Reisfeld B; Yang RS; Lenaerts AJ
Antimicrob Agents Chemother; 2013 Apr; 57(4):1763-71. PubMed ID: 23357766
[TBL] [Abstract][Full Text] [Related]
2. Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model.
Lyons MA; Lenaerts AJ
J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):375-89. PubMed ID: 26026426
[TBL] [Abstract][Full Text] [Related]
3. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs.
Goutelle S; Bourguignon L; Maire PH; Van Guilder M; Conte JE; Jelliffe RW
Antimicrob Agents Chemother; 2009 Jul; 53(7):2974-81. PubMed ID: 19380594
[TBL] [Abstract][Full Text] [Related]
4. Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans.
Zurlinden TJ; Eppers GJ; Reisfeld B
Antimicrob Agents Chemother; 2016 Aug; 60(8):4860-8. PubMed ID: 27270284
[TBL] [Abstract][Full Text] [Related]
5. Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients.
te Brake LH; Ruslami R; Later-Nijland H; Mooren F; Teulen M; Apriani L; Koenderink JB; Russel FG; Burger DM; Alisjahbana B; Wieringa F; van Crevel R; Aarnoutse RE
Antimicrob Agents Chemother; 2015; 59(6):3233-9. PubMed ID: 25801554
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling.
Srivastava S; Sherman C; Meek C; Leff R; Gumbo T
Antimicrob Agents Chemother; 2011 Nov; 55(11):5085-9. PubMed ID: 21896907
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes.
Ruslami R; Nijland HM; Adhiarta IG; Kariadi SH; Alisjahbana B; Aarnoutse RE; van Crevel R
Antimicrob Agents Chemother; 2010 Mar; 54(3):1068-74. PubMed ID: 20038625
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of rifampin in the treatment of Mycobacterium tuberculosis in Asian elephants.
Egelund EF; Isaza R; Brock AP; Alsultan A; An G; Peloquin CA
J Vet Pharmacol Ther; 2015 Apr; 38(2):137-43. PubMed ID: 25236765
[TBL] [Abstract][Full Text] [Related]
9. Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis.
Sloan DJ; McCallum AD; Schipani A; Egan D; Mwandumba HC; Ward SA; Waterhouse D; Banda G; Allain TJ; Owen A; Khoo SH; Davies GR
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28461315
[TBL] [Abstract][Full Text] [Related]
10. Mathematical modeling of pulmonary tuberculosis therapy: Insights from a prototype model with rifampin.
Goutelle S; Bourguignon L; Jelliffe RW; Conte JE; Maire P
J Theor Biol; 2011 Aug; 282(1):80-92. PubMed ID: 21605569
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
Rockwood N; Meintjes G; Chirehwa M; Wiesner L; McIlleron H; Wilkinson RJ; Denti P
Antimicrob Agents Chemother; 2016 Oct; 60(10):6050-9. PubMed ID: 27480859
[TBL] [Abstract][Full Text] [Related]
12. A physiologically based pharmacokinetic model for capreomycin.
Reisfeld B; Metzler CP; Lyons MA; Mayeno AN; Brooks EJ; Degroote MA
Antimicrob Agents Chemother; 2012 Feb; 56(2):926-34. PubMed ID: 22143528
[TBL] [Abstract][Full Text] [Related]
13. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
McIlleron H; Wash P; Burger A; Norman J; Folb PI; Smith P
Antimicrob Agents Chemother; 2006 Apr; 50(4):1170-7. PubMed ID: 16569826
[TBL] [Abstract][Full Text] [Related]
14. Determination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimaging.
DeMarco VP; Ordonez AA; Klunk M; Prideaux B; Wang H; Zhuo Z; Tonge PJ; Dannals RF; Holt DP; Lee CK; Weinstein EA; Dartois V; Dooley KE; Jain SK
Antimicrob Agents Chemother; 2015 Sep; 59(9):5768-74. PubMed ID: 26169396
[TBL] [Abstract][Full Text] [Related]
15. ISONIAZID AND RIFAMPIN PHARMACOKINETICS IN TWO ASIAN ELEPHANTS (ELEPHAS MAXIMUS) INFECTED WITH MYCOBACTERIUM TUBERCULOSIS.
Egelund EF; Isaza R; Alsultan A; Peloquin CA
J Zoo Wildl Med; 2016 Sep; 47(3):868-871. PubMed ID: 27691967
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.
López-Cortés LF; Ruiz-Valderas R; Viciana P; Alarcón-González A; Gómez-Mateos J; León-Jimenez E; Sarasanacenta M; López-Pua Y; Pachón J
Clin Pharmacokinet; 2002; 41(9):681-90. PubMed ID: 12126459
[TBL] [Abstract][Full Text] [Related]
17. In silico evaluation and exploration of antibiotic tuberculosis treatment regimens.
Pienaar E; Dartois V; Linderman JJ; Kirschner DE
BMC Syst Biol; 2015 Nov; 9():79. PubMed ID: 26578235
[TBL] [Abstract][Full Text] [Related]
18. Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India.
Aruldhas BW; Hoglund RM; Ranjalkar J; Tarning J; Mathew SK; Verghese VP; Bose A; Mathew BS
Br J Clin Pharmacol; 2019 Mar; 85(3):644-654. PubMed ID: 30588647
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.
Thee S; Seddon JA; Donald PR; Seifart HI; Werely CJ; Hesseling AC; Rosenkranz B; Roll S; Magdorf K; Schaaf HS
Antimicrob Agents Chemother; 2011 Dec; 55(12):5560-7. PubMed ID: 21968358
[TBL] [Abstract][Full Text] [Related]
20. A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment.
Pienaar E; Cilfone NA; Lin PL; Dartois V; Mattila JT; Butler JR; Flynn JL; Kirschner DE; Linderman JJ
J Theor Biol; 2015 Feb; 367():166-179. PubMed ID: 25497475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
